A study analyzed data from over 1.5 million patients with type 2 diabetes to investigate the impact of antidiabetic medications on dementia and Alzheimer’s disease (AD) risk. Results showed that metformin and SGLT-2 inhibitors were associated with significantly lower risks of dementia and AD compared to other antidiabetic drugs. The study highlights the importance of considering both metabolic and cognitive health outcomes in diabetes management, especially in elderly patients. This research suggests potential cognitive benefits of SGLT-2 inhibitors, providing significant clinical implications for diabetes management. The study emphasizes the need for individualized treatment approaches based on patient-specific factors.
Source link
Study reveals potential cognitive benefits of antidiabetic drugs
